S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

AIM AIM ImmunoTech Inc

0.13281

-0.00549 (-3.97%)

Last Updated: 09:44:47

Delayed by 15 minutes

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more AIM ImmunoTech Charts.

AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more AIM ImmunoTech Charts.

AIM ImmunoTech Inc News

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Thursday 20 February 2025 (4 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 19 February 2025 (5 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 19 February 2025 (5 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 11 February 2025 (2 weeks ago) • Edgar (US Regulatory)

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
Tuesday 11 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 11 February 2025 (2 weeks ago) • Edgar (US Regulatory)

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
Tuesday 11 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 7 February 2025 (2 weeks ago) • Edgar (US Regulatory)

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
Friday 7 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 5 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
Wednesday 5 February 2025 (3 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Monday 3 February 2025 (3 weeks ago) • Edgar (US Regulatory)

More AIM ImmunoTech Inc News Articles

Intergrated Cannabis Sol... (PK)

Accredited Solutions (PK)

Adia Nutrition (PK)

Northwest Biotherapeutics (QB)

Lightwave Logic

Bioelectronics (PK)

Anavex Life Sciences

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions